Hancock Whitney Corp Eagle Pharmaceuticals, Inc. Transaction History

Hancock Whitney Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 09, 2021	SELL	$36.86 - $44.5 $200,260 - $241,768	-5,433 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $219,058 - $276,920	5,433 New	5,433 $227,000
Q4 2020 Feb 09, 2021	SELL	$41.72 - $51.34 $230,085 - $283,140	-5,515 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$37.02 - $51.28 $7,737 - $10,717	209 Added 3.94%	5,515 $234,000
Q2 2020 Jul 30, 2020	SELL	$43.24 - $55.02 $92,101 - $117,192	-2,130 Reduced 28.64%	5,306 $255,000
Q1 2020 May 08, 2020	SELL	$34.37 - $60.07 $158,789 - $277,523	-4,620 Reduced 38.32%	7,436 $342,000
Q4 2019 Feb 06, 2020	BUY	$54.32 - $64.31 $161,656 - $191,386	2,976 Added 32.78%	12,056 $724,000
Q3 2019 Oct 29, 2019	SELL	$53.25 - $59.98 $32,003 - $36,047	-601 Reduced 6.21%	9,080 $514,000
Q2 2019 Aug 29, 2019	BUY	$46.61 - $58.45 $451,231 - $565,854	9,681 New	9,681 $539,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

Stay updated on Hancock Whitney Corp with notifications on news.